| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454765 | Lung Cancer | 2016 | 7 Pages |
Abstract
We found large variation across studies in ERCC1 evaluation procedures. This will limit the future comparability of results between these different studies. To enable evidence-based clinical practice, consensus is needed on a validated procedure to assess a predictive biomarker in the early phase of research. We believe that ERCC1 is not untypical of biomarkers being investigated for stratified medicine.
Keywords
PD-L1RTqPCRNERClinical trials as topicHumanImmunohistochemistryIHCexcision repair cross-complementation group 1nucleotide excision repairDrug therapyAntineoplastic therapyNon-small-cell lungNon-small-cell lung cancerNSCLCfluorescence in situ hybridizationFishbiological markersERCC1Carcinomanot reported
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kinga Malottki, Sanjay Popat, Jonathan J. Deeks, Richard D. Riley, Andrew G. Nicholson, Lucinda Billingham,